CAFC-PTOOctober 8, 2026·26-1071·Dismissed.
Sarepta Therapeutics, Inc. v. Trustees of the University of Pennsylvania
Patent Trial and Appeal Board
Holding
On the parties' agreement, the Federal Circuit dismissed the appeal from the PTAB's decision in IPR2024-00580 under Fed. R. App. P. 42(b), with each side bearing its own costs. The order does not reach the merits.
Why It Matters
The appeal from the IPR ended by agreement without any merits ruling, so the order provides no guidance on the underlying patent issues and leaves the PTAB proceeding's result as is.
Full Summary
Sarepta Therapeutics, Inc. v. Trustees of the University of Pennsylvania
On the parties' agreement, the Federal Circuit dismissed the appeal from the PTAB's decision in IPR2024-00580 under Fed. R. App. P. 42(b), with each side bearing its own costs. The order does not reach the merits.
The appeal from the IPR ended by agreement without any merits ruling, so the order provides no guidance on the underlying patent issues and leaves the PTAB proceeding's result as is.
Dismissed.
Sarepta appealed from a PTAB decision in IPR2024-00580; the University of Pennsylvania's Trustees and REGENXBIO were appellees.
The parties agreed to dismissal, and the court dismissed the proceeding under Fed. R. App. P. 42(b).
Each side bears its own costs.
The order states no reasons, does not describe the patents, claims, or PTAB ruling, and decides no patent-law issue.
The mandate issued the same day, October 8, 2026.
standing / jurisdiction non-precedential
Key Points
- Sarepta appealed from a PTAB decision in IPR2024-00580; the University of Pennsylvania's Trustees and REGENXBIO were appellees.
- The parties agreed to dismissal, and the court dismissed the proceeding under Fed. R. App. P. 42(b).
- Each side bears its own costs.
- The order states no reasons, does not describe the patents, claims, or PTAB ruling, and decides no patent-law issue.
- The mandate issued the same day, October 8, 2026.